

NCT03096613 Raw comparison:

Summary:
CHIA has 21 criteria while your personal folder has 22 criteria
Total found criteria: 21/21
Total not Found: 0/21
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Aged 18 years or older male or female              │ Aged 18 years or older male or female              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Systolic heart failure with New York Heart         │ Systolic heart failure with New York Heart         │
│ Association (NYHA) class II-III                    │ Association (NYHA) class II-III                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction (LVEF) less     │ Left ventricular ejection fraction (LVEF) less     │
│ than 40% by echocardiography during screening and  │ than 40% by echocardiography during screening and  │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ SCH (TSH upper limits of normal (ULN) -10mIU/L and │ SCH (TSH upper limits of normal (ULN) -10mIU/L and │
│ FT4 level within reference range)                  │ FT4 level within reference range)                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Having received standard HF therapy for at least 2 │ Having received standard HF therapy for at least 2 │
│ weeks having reached target dose or max tolerable  │ weeks having reached target dose or max tolerable  │
│ dose                                               │ dose                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Provided informed consent                          │ Provided informed consent                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute heart failure or acute exacerbation of       │ Acute heart failure or acute exacerbation of       │
│ chronic heart failure within the past 2 weeks      │ chronic heart failure within the past 2 weeks      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Scheduled cardiac resynchronization therapy or     │ Scheduled cardiac resynchronization therapy or     │
│ heart transplantation                              │ heart transplantation                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignant tumor or life expectancy      │ History of malignant tumor or life expectancy      │
│ under 12 months                                    │ under 12 months                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Already on medications that may affect thyroid     │ Already on medications that may affect thyroid     │
│ function (L-T4 carbimazole propylthiouracil        │ function (L-T4 carbimazole propylthiouracil        │
│ amiodarone lithium)                                │ amiodarone lithium)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy and lactation period                     │ Pregnancy and lactation period                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in another clinical trial within the │ Participation in another clinical trial within the │
│ past 30 days                                       │ past 30 days                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindication or intolerance to evidence-based  │ Contraindication or intolerance to evidence-based  │
│ therapy for CHF such as beta-blocker angiotensin-  │ therapy for CHF such as beta-blocker angiotensin-  │
│ converting enzyme inhibitor or angiotensin         │ converting enzyme inhibitor or angiotensin         │
│ receptor blocker                                   │ receptor blocker                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity to the trial treatment(s)   │ Known hypersensitivity to the trial treatment(s)   │
│ or diluents (when applicable) including placebo or │ or diluents (when applicable) including placebo or │
│ other comparator drug(s)                           │ other comparator drug(s)                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated adrenal insufficiency                    │ Untreated adrenal insufficiency                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated pituitary insufficiency                  │ Untreated pituitary insufficiency                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated thyrotoxicosis                           │ Untreated thyrotoxicosis                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with levothyroxine must not be initiated │ Treatment with levothyroxine must not be initiated │
│ in patients with acute myocardial infarction acute │ in patients with acute myocardial infarction acute │
│ myocarditis or acute pancarditis                   │ myocarditis or acute pancarditis                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe renal dysfunction (eGFR=30 ml/min/1 73m2)   │ Severe renal dysfunction (eGFR≤30 ml/min/1 73m2)   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant hepatic impairment (Serum GPT > 120    │ Significant hepatic impairment (Serum GPT \> 120   │
│ U/L)                                               │ U/L)                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any disorder which in the opinion of the           │ Any disorder which in the opinion of the           │
│ investigator might jeopardise subject's safety or  │ investigator might jeopardise subject's safety or  │
│ compliance with the protocol                       │ compliance with the protocol                       │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛